RELATED CONTENT
NEWS
- NICE decision puts down a marker for drug development
- Data cast more doubt on Avastin's benefit in older NSCLC patients
- NICE rejects Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second line mCRC
- Idera holds out hope for IMO-2055 after negative Phase II head and neck cancer data
ANALYSIS
Other Informa Analysis
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK

Section Head (m/f)
DRA International/CIS Section

Section Head (m/f)
DRA International/CIS Section

